{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002790","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.585293+00:00","generated_at":"2026-06-16T02:10:24.201207+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCryst Q1 ORLADEYO revenue $68.4M (+38% YoY); net loss narrows to $53.3M","bullets":["ORLADEYO net revenue $68.4M in Q1 2023 (+37.6% YoY); 46% more U.S. patients on therapy vs Q1 2022.","Over 1,000 U.S. patients on ORLADEYO; new patient start forms up 20% YoY in Q1.","Full-year 2023 ORLADEYO net revenue guidance set at no less than $320M.","Entered new $450M loan agreement with Pharmakon; $300M drawn to repay Athyrium debt.","R&D expense reduced 26% YoY to $48.4M; SG&A rose 39.6% to $47.9M on commercial investment."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002790","json":"https://secwatch.observer/filing/0001171843-23-002790.json","markdown":"https://secwatch.observer/filing/0001171843-23-002790.md","text":"https://secwatch.observer/filing/0001171843-23-002790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/0001171843-23-002790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/f8k_050323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:10:24.201207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d82e2342f88f1fdfda6f5874fa866d334a30230","claim":"BIOCRYST PHARMACEUTICALS INC reported first quarter ended March 31, 2023 results: revenue $68.8 million, net income Net loss of $53.3 million, or $0.28 per share, EPS $0.28 per share. Guidance reaffirmed.","evidence_excerpt":"For the three months ended March 31, 2023, total revenues were $68.8 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/0001171843-23-002790-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$68.8 million"},{"label":"Net income","value":"Net loss of $53.3 million, or $0.28 per share"},{"label":"EPS","value":"$0.28 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b3c1022cf825fb32081f716051af7772d6bcebdb","claim":"BIOCRYST PHARMACEUTICALS INC updated its full year 2023 guidance (reaffirmed).","evidence_excerpt":"The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/0001171843-23-002790-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}